Analysts Set Altimmune, Inc. (NASDAQ:ALT) PT at $20.83

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $20.83.

ALT has been the subject of several analyst reports. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, April 3rd.

Altimmune Price Performance

Shares of ALT stock traded up $0.24 during trading hours on Thursday, hitting $4.79. The stock had a trading volume of 2,220,384 shares, compared to its average volume of 2,890,097. The stock's 50 day moving average is $5.38 and its 200 day moving average is $6.73. The firm has a market capitalization of $368.90 million, a PE ratio of -3.09 and a beta of 0.91. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts predict that Altimmune will post -1.35 earnings per share for the current year.

Insider Activity

In related news, CFO Gregory L. Weaver purchased 10,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in shares of Altimmune by 214.2% during the 1st quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock valued at $34,000 after buying an additional 4,598 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune during the fourth quarter valued at approximately $45,000. Magnus Financial Group LLC purchased a new stake in shares of Altimmune during the first quarter valued at approximately $50,000. Virtus ETF Advisers LLC acquired a new position in shares of Altimmune during the fourth quarter worth $60,000. Finally, Cullen Frost Bankers Inc. purchased a new position in shares of Altimmune in the fourth quarter valued at $72,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.